Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A C-Glycosylisoflavone compound of the formula (I) having alkylaminoalkoxyl substituent or a pharmaceutically acceptable salt thereof:



(I)

wherein, R_1 and R_2 are independently selected from the group consisting of hydrogen, (C_1-C_{12}) linear or branched alkylamino (C_1-C_6)alkyl, mono- or di-(C_{3-8})cycloalkylamino-C_{1-6}alkyl, [[or]]and (C_5-C_{14})heterocyclic-(C_1-C_6)alkyl; R_3 is selected from the group consisting of hydrogen, (C_1-C_{12}) linear or branched acyl[[, or]] and C_{6-14} aryl carbonyl; wherein R_1 and R_2 do

not represent hydrogen simultaneously; the 1-positionof D-glucosyl is connected with the 8-position of the isoflavone in a form of β-configured C-glycoside, wherein the mono- or di-(C_{3-8})cycloalkylamino group of the mono- or di-(C_{3-8})cycloalkylamino-C_{1-6}alkyl includes pyrrolidinyl and morpholinyl, and the (C_5-C_{14})heterocyclic group of the (C_5-C_{14})heterocyclic-(C_1-C_6)alkyl is selected from the group consisting of piperidyl, piperazinyl, N-methylpiperazinyl, and N-ethylpiperazinyl.

2. (Currently Amended) The compound according to claim 1, characterized in that in formula [[(2)]] (I), R_1 and R_2 are independently selected from the group consisting of hydrogen, dimethylaminoethyl, diethylaminoethyl, di(n-propyl)aminoethyl, di(iso-propyl)aminoethyl, di(n-butyl)aminoethyl, di(iso-butyl)aminoethyl, di(tert-butyl)aminoethyl, pyrrolidinylethyl, piperidylethyl, morpholinylethyl, piperazinylethyl, N-methylpiperazinylethyl, N-ethylpiperazinylethyl, tert-butylaminoethyl, dicyclohexylaminoethyl, dimethylaminopropyl, diethylaminopropyl, di(n-propyl)aminopropyl, di(iso-propyl)aminopropyl, di(n-butyl)aminopropyl, di(iso-butyl)aminopropyl, di(tert-butyl)aminopropyl, pyrrolidinylpropyl, piperidylpropyl, morpholinylpropyl, piperazinylpropyl, N-methylpiperazinylpropyl, N-ethylpiperazinylpropyl, tert-butylaminopropyl, dicyclohexylaminopropyl, dimethylaminobutyl, diethylaminobutyl, di(n-propyl)aminobutyl, di(iso-propyl)aminobutyl, di(n-butyl)aminobutyl, di(iso-butyl)aminobutyl, di(tert-butyl)aminobutyl, pyrrolidinylbutyl, piperidylbutyl, morpholinylbutyl, piperazinylbutyl, N-methylpiperazinylbutyl, N-ethylpiperazinylbutyl, tert-butylaminobutyl, and dicyclohexylaminobutyl, wherein R_1 and R_2 do not represent hydrogen simultaneously; R_3 is selected from the group consisting of hydrogen, propionyl, butyryl, isobutyryl, 2-methylbutyryl, 3-methylbutyryl, 2,2-dimethylpropionyl, valeryl, caproyl, heptanoyl, octanoyl, nonanoyl, decanoyl, and lauroyl; [[or a]] and wherein the pharmaceutically acceptable salt is selected from the group consisting of [[the]] salts of hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, sulfuric acid, methane sulfonic acid, p-toluene sulfonic acid, maleic acid, fumaric acid, tartaric acid, and various natural or non-natural amino acids.

3. (Currently Amended) The compound according to claim 1, wherein the compound of the formula (I) is selected from the group consisting of:

4'-(3-N-piperidylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(3-N-morpholinylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(3-N-pyrrolidinylpropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(3-diethylaminopropoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-[3-di(n-propyl)aminopropoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

4'-[3-di(n-butyl)aminopropoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

4'-[3-(4-methylpiperazinyl)propoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

4'-[3-(4-ethylpiperazinyl)propoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

4'-(4-N-piperidylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-N-morpholinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-N-pyrrolidinylbutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-diethylaminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)isoflavone,

4'-(4-di(n-propyl)aminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl)- isoflavone,

4'-(4-di(n-butyl)aminobutoxy)-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

4'-[4-(4-methylpiperazinyl)butoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

4'-[4-(4-ethylpiperazinyl)butoxy]-7-hydroxy-8-β-D-(1-deoxyglucosyl) isoflavone,

[[or]] and a pharmaceutically acceptable salt thereof.

4. (Currently Amended) A pharmaceutical composition comprising [[a]] the C-Glycosylisoflavone compound of claim 1 and a pharmaceutically acceptable carrier.

5. (Currently amended) A preparation method of [[a]] the C-Glycosylisoflavone compound of claim 1, characterized in comprising, reacting puerarin material with a corresponding ~~suitable~~ bis-functional group substituted compound ~~such as a bihalogenated hydrocarbon, an alkylene bissulfonate, or a halogenated hydrocarbon monosulfonate etc.~~, in a suitable solvent selected from water, acetone, dimethylformamide, dimethyl sulfoxide, and lower alcohols, under the presence of a base, an ambient to reflux- temperature, which is firstly mono-etherified followed by amination and/or salt-formation, to give the corresponding alkylaminoalkoxyl-substituted C-Glycosylisoflavone compound or a pharmaceutically acceptable salt thereof.

6. (Currently amended) ~~Use of a compound of claim 1 in the manufacture of a medicament~~ A method for [[the]] treatment of cardio- and cerebrovascular diseases as well as ~~a medicament for the treatment of~~ hypoxia or ischemia, comprising administering a therapeutically effective amount of the C-Glycosylisoflavone compound of claim 1 to a patient in need.

7. (Currently amended) ~~Use of a compound of claim 1 in the manufacture of a medicament~~ A method for [[the]] treatment of diabetes as well as diabetic complications, comprising administering a therapeutically effective amount of the C-Glycosylisoflavone compound of claim 1 to a patient in need.

8. (Currently amended) ~~Use of a compound of claim 1 in the manufacture of a medicament~~ A method for [[the]] treatment of chemical poisoning, ~~particularly alcoholism~~ comprising administering a therapeutically effective amount of the C-Glycosylisoflavone compound of claim 1 to a patient in need.

9. (New) The preparation method as set forth in claim 5, wherein said bis-functional group substituted compound is selected from the group consisting of a bihalogenated hydrocarbon, an alkylene bissulfonate, and a halogenated hydrocarbon monosulfonate.

10. (New) The method as set forth in claim 8, wherein said chemical poisoning is alcohol poisoning.